摘要
目的观察沙利度胺联合紫杉醇＋顺铂（TP）方案治疗晚期非小细胞肺癌（NSCLC）患者的疗效及安全性。方法随机选择晚期NSCLC患者70例,按年龄分为两组,老年组（≥60岁）34例,非老年组（〈60岁）36例,均给予沙利度胺联合TP方案治疗,21天为1个周期,至少接受2个周期的治疗。观察两组患者近期疗效、生活质量状况及不良反应。结果老年组和非老年组有效率分别为40.6%（13/32）和42.9%（15/35）,疾病控制率分别为87.5%（28/32）和88.6%（31/35）,两组中位无进展生存期分别为7.67个月和8.98个月,中位总生存期分别为11.86个月和12.60个月,两组患者治疗后生活质量状况比较差异无统计学意义（P〉0.05）。不良反应方面,两组均以Ⅰ～Ⅱ级脱发、白细胞减少、肌肉关节痛及恶心呕吐为主,均在可耐受范围,两组不良反应发生率差异无统计学意义（P〉0.05）。结论老年晚期NSCLC患者给予沙利度胺联合TP方案治疗得到与非老年晚期NSCLC患者一样的治疗效果。
Objective To study the curative effect and safety of thalidomide combined with paclitaxel plus cisplatinum（TP）chemotherapy in patients with advanced non-small cell lung cancer（NSCLC）.Methods Seventy patients in late NSCLC period were divided randomly into two groups according to the age.The elderly group（≥60years）34patients and non-elderly group（〈60 years）36 patients were treated with thalidomide combined with TP chemotherapy.All patients received treatments for at least two periods,21 days for one period.The efficacy,the quality of life and adverse effects of two groups were observed.Results The effective rate for advanced NSCLC in the elderly group and the non-elderly group was 40.6%（13/32）and 42.9%（15/35）,respectively.Control rate of the disease was87.5%（28/32）and 88.6%（31/35）,the median progression-free survival was 7.67 months and 8.98 months,and the median overall survival was 11.86 months and 12.60 months,respectively.The patients of two groups improved quality of life compared with the previous situation,but the quality of life showed no significant differences after treatment between two groups（P 〉0.05）.In the adverse effects,the Ⅰ-Ⅱ toxic reactions of chemotherapy were tolerable,including alopecia,leukopenia,muscle and joint pain,nausea and vomiting,but two groups were similar（P〉 0.05）.Conclusion If elderly patients with late NSCLC period are treated with thalidomide plus TP chemotherapy,they get as safe and effective treatment as non-elderly patients with late NSCLC period.
出处
《临床荟萃》
CAS
2014年第9期988-991,共4页
Clinical Focus
基金
河北省衡水市科技局科学技术研究与发展计划项目(09008A)
关键词
癌
非小细胞肺
抗肿瘤联合化疗方案
顺铂
老年人
carcinoma
non-small-cell lung
antineoplastic combined chemotherapy protocols
cisplatin
aged
